Transcriptional regulation of genes by MYCN in PAX3::FOXO1 -positive rhabdomyosarcomas and their roles in cell cycle progression
Transcriptional regulation of genes by MYCN in PAX3::FOXO1 -positive rhabdomyosarcomas and their roles in cell cycle progression
Background: MYCN amplification and high expression is associated with pediatric malignancies including neuroblastoma and alveolar rhabdomyosarcoma. MYCN transcription in alveolar rhabdomyosarcomas is driven by a feedback loop with the PAX3::FOXO1 fusion protein. However, the role of MYCN is not well-defined.
Methods: Chromatin ImmunoPrecipitation (ChIP)-sequencing of alveolar rhabdomyosarcoma cell lines was used to identify genome-wide MYCN binding sites. Ontology analyses of genes adjacent to MYCN binding sites corresponding to expression changes after siRNA reduction was performed and confirmed by ChIP-qPCR. Cells from each phase of the cell cycle were isolated by Fluorescence Activated Cell Sorting for assessing protein expression by Western blotting.
Results: genes encoding transcription factors adjacent to MYCN binding sites and genes with binding sites proximal to their promoters were strongly associated with RNA synthesis and cell cycle pathways, respectively. MYCN binding sites in regions that positively correlated with gene expression changes were linked to cell cycle regulation, consistent with phenotypic absence of cell cycle checkpoint control. Cell cycle regulated genes CDK4 and KDM4B were validated as MYCN-regulated and, in-keeping with unchecked cell cycle progression, expressed throughout the cell cycle, coincident with MYCN.
Conclusions: MYCN binding sites associated with gene expression changes defined the contribution of MYCN to the transcriptional control of key pathways/molecular processes in the development and progression of rhabdomyosarcomas. MYCN aberrantly regulated CDK4 and KDM4B expression throughout the cell cycle in PAX3::FOXO1 positive rhabdomyosarcoma. The regulatory network defined supports MYCN, CDK4 and KDM4B as therapeutic targets in the treatment of rhabdomyosarcoma patients.
CDK6, Cell cycle, ChIP-sequencing, KDM4B, MYCN, Rhabdomyosarcoma
Walters, Zoe S.
e1ccd35d-63a9-4951-a5da-59122193740d
Leongamornlert, Daniel
d2bcf8a6-c67d-496f-b61a-b31066b07a1d
Villarejo-Balcells, Barbara
8c5a21f6-263e-4304-a2c5-9e499333d305
Tse, Carmen
22250af6-10f5-4443-b10e-e7dbba722306
Pengelly, Reuben
af97c0c1-b568-415c-9f59-1823b65be76d
Titley, Ian
4f488f29-d832-4538-b6c6-f31a504cf973
Shipley, Janet
c4bd3760-d826-42ba-8321-ce78582034ac
25 April 2025
Walters, Zoe S.
e1ccd35d-63a9-4951-a5da-59122193740d
Leongamornlert, Daniel
d2bcf8a6-c67d-496f-b61a-b31066b07a1d
Villarejo-Balcells, Barbara
8c5a21f6-263e-4304-a2c5-9e499333d305
Tse, Carmen
22250af6-10f5-4443-b10e-e7dbba722306
Pengelly, Reuben
af97c0c1-b568-415c-9f59-1823b65be76d
Titley, Ian
4f488f29-d832-4538-b6c6-f31a504cf973
Shipley, Janet
c4bd3760-d826-42ba-8321-ce78582034ac
Walters, Zoe S., Leongamornlert, Daniel, Villarejo-Balcells, Barbara, Tse, Carmen, Pengelly, Reuben, Titley, Ian and Shipley, Janet
(2025)
Transcriptional regulation of genes by MYCN in PAX3::FOXO1 -positive rhabdomyosarcomas and their roles in cell cycle progression.
European Journal of Cancer Paediatric Oncology, 5, [100230].
(doi:10.1016/j.ejcped.2025.100230).
Abstract
Background: MYCN amplification and high expression is associated with pediatric malignancies including neuroblastoma and alveolar rhabdomyosarcoma. MYCN transcription in alveolar rhabdomyosarcomas is driven by a feedback loop with the PAX3::FOXO1 fusion protein. However, the role of MYCN is not well-defined.
Methods: Chromatin ImmunoPrecipitation (ChIP)-sequencing of alveolar rhabdomyosarcoma cell lines was used to identify genome-wide MYCN binding sites. Ontology analyses of genes adjacent to MYCN binding sites corresponding to expression changes after siRNA reduction was performed and confirmed by ChIP-qPCR. Cells from each phase of the cell cycle were isolated by Fluorescence Activated Cell Sorting for assessing protein expression by Western blotting.
Results: genes encoding transcription factors adjacent to MYCN binding sites and genes with binding sites proximal to their promoters were strongly associated with RNA synthesis and cell cycle pathways, respectively. MYCN binding sites in regions that positively correlated with gene expression changes were linked to cell cycle regulation, consistent with phenotypic absence of cell cycle checkpoint control. Cell cycle regulated genes CDK4 and KDM4B were validated as MYCN-regulated and, in-keeping with unchecked cell cycle progression, expressed throughout the cell cycle, coincident with MYCN.
Conclusions: MYCN binding sites associated with gene expression changes defined the contribution of MYCN to the transcriptional control of key pathways/molecular processes in the development and progression of rhabdomyosarcomas. MYCN aberrantly regulated CDK4 and KDM4B expression throughout the cell cycle in PAX3::FOXO1 positive rhabdomyosarcoma. The regulatory network defined supports MYCN, CDK4 and KDM4B as therapeutic targets in the treatment of rhabdomyosarcoma patients.
Text
1-s2.0-S2772610X25000170-main
- Version of Record
Text
Supplementary material 1
Spreadsheet
Supplementary material 2
More information
Accepted/In Press date: 11 April 2025
e-pub ahead of print date: 17 April 2025
Published date: 25 April 2025
Keywords:
CDK6, Cell cycle, ChIP-sequencing, KDM4B, MYCN, Rhabdomyosarcoma
Identifiers
Local EPrints ID: 501319
URI: http://eprints.soton.ac.uk/id/eprint/501319
ISSN: 2772-610X
PURE UUID: c195e73c-0789-47be-aa70-8270381ea33b
Catalogue record
Date deposited: 28 May 2025 17:17
Last modified: 22 Aug 2025 02:20
Export record
Altmetrics
Contributors
Author:
Daniel Leongamornlert
Author:
Barbara Villarejo-Balcells
Author:
Carmen Tse
Author:
Ian Titley
Author:
Janet Shipley
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics